# Hi-Lab

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/hi-lab

- Industry: Biotechnology
- Headquarters: Beijing, China
- Total disclosed funding: $8.5M
- Latest round: Angel (Dec 25, 2025)
- Investors on record: 5

## About

Based in Beijing, China and founded in 2022, Hi-Lab (Beijing) Biotechnology Co., Ltd., dba Hi-Lab,  focuses on advancing the discovery and development of First-in-Class and Best-in-Class antibody drug candidates. The company engages in domestic and international pipeline collaborations to support global biopharmaceutical innovation. The company conducts research and development of multi-specific and bispecific antibody therapeutics with applications in cancer, autoimmune, and metabolic disease treatment. Its services include biologic design, preclinical evaluation, and partnership-driven clinical development support. The company generates revenue from research collaborations, licensing of its therapeutic technologies, and development partnerships with biopharmaceutical organizations.
In December 2025, Hi-Lab closed nearly CNY 60 million in Angel funding led by YuanBio Venture, with participation from new investors Tsinghua Innovation Ventures, Beishang Capital, Flyfot Ventures and Zero2IPO Ventures.

## Funding rounds

- Angel, Dec 25, 2025, $8.5M — Zero2IPO Ventures, YuanBio Venture, Tsinghua Innovation Ventures, Beishang Capital, Flyfot Ventures

## Investors

- Zero2IPO Ventures (https://capitalatlas.ai/funds/zero2ipo-ventures) — Angel
- YuanBio Venture (https://capitalatlas.ai/funds/yuanbio-venture) — Angel
- Tsinghua Innovation Ventures (https://capitalatlas.ai/funds/tsinghua-innovation-ventures) — Angel
- Beishang Capital (https://capitalatlas.ai/funds/beishang-capital) — Angel
- Flyfot Ventures (https://capitalatlas.ai/funds/flyfot-ventures) — Angel